kabutan

SymBio Pharma, Jul-Sep (3Q) Net Income Loss Narrows

Thu Oct 30, 2025 3:30 pm JST Earnings

4582 SymBio Pharmaceuticals Limited 【J-GAAP】

Earnings Report

SymBio Pharmaceuticals Limited <4582> [TSE Growth] announced its financial results after the market closed on October 30th (15:30). The consolidated net loss for the cumulative third quarter of the fiscal year ending December 2025 (January to September) expanded to a loss of 3.56 billion yen (compared to a loss of 2.84 billion yen in the same period last year).

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net loss for the October to December period (4Q) is expected to nearly flat at loss of 1.02 billion yen (compared to a loss of 0.98 billion yen in the same period last year).

In the most recent three-month period, from July to September (3Q), the consolidated net loss improved to a deficit of 1.19 billion yen (compared to a loss of 1.30 billion yen in the same period last year). However, the operating profit/loss margin drastically worsened from -174.6% in the same period last year to -365.7%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2023 4,421 -283 -156 -788 -19.9 ー Nov 14, 2023 J-GAAP
Jan - Sep, 2024 1,898 -2,791 -2,759 -2,845 -63.4 ー Oct 31, 2024 J-GAAP
Jan - Sep, 2025 970 -3,339 -3,538 -3,565 -73.5 ー Oct 30, 2025 J-GAAP
YoY -48.9% -19.6% -28.2% -25.3% -15.8%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 1,168 -2,157 -2,208 -2,292 -50.8 0 Feb 6, 2025 J-GAAP
Jul - Dec, 2025 Guidance 754 -2,108 -2,127 -2,223 -40.8 0 Jul 31, 2025 J-GAAP
YoY -35.4% +2.3% +3.7% +3.0% +19.8%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 5,589 -811 -736 -1,962 -49.2 0 Feb 8, 2024 J-GAAP
Dec, 2024 2,452 -3,876 -3,689 -3,833 -85.0 0 Feb 6, 2025 J-GAAP
Dec, 2025 Guidance 1,400 -4,262 -4,467 -4,592 -84.2 0 Jun 10, 2025 J-GAAP
YoY -42.9% -10.0% -21.1% -19.8% +1.0%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 614 -1,072 -1,278 -1,304 -29.1 -174.6 Oct 31, 2024 J-GAAP
Oct - Dec, 2024 554 -1,085 -930 -988 -21.9 -195.8 Feb 6, 2025 J-GAAP
Jan - Mar, 2025 264 -1,169 -1,288 -1,321 -28.0 -442.8 May 8, 2025 J-GAAP
Apr - Jun, 2025 382 -985 -1,052 -1,048 -21.8 -257.9 Jul 31, 2025 J-GAAP
Jul - Sep, 2025 324 -1,185 -1,198 -1,196 -24.6 -365.7 Oct 30, 2025 J-GAAP
YoY -47.2% -10.5% +6.3% +8.3% +15.2%

Related Articles